ClinicalTrials.gg
CompletedNCT01689129EDITION JP IUpdated Jun 9, 2014

Comparison of a New Formulation of Insulin Glargine With Lantus® in Japanese Patients With Type 1 Diabetes Mellitus

A Phase 3 interventional study of Insulin glargine new formulation (HOE901) and Insulin glargine (HOE901) (Lantus) in Type 1 Diabetes Mellitus, sponsored by Sanofi. Completed at 22 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-06-09.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
243
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 — none open to participants now, none under way, none of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 1.

Enrollment
17th of 66
243 · median 73
Started
2012
with 7 others
Phase 3
18 of 66
none open now
Registered
40th of 66
by date
Lead sponsor
24 of 66
Sanofi

Among the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1, this one is the 17th largest by enrollment, is one of 8 that started in 2012, is one of 18 in phase 3, and was the 40th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

None of the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 is open now. The open studies under Diabetes Mellitus, Type 1, anywhere →

About Insulin Glargine

Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 412 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 258 (63%) stop at 75 or younger; 185 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 as a file.
02

Study summary

Primary Objective:

To compare the efficacy of a new formulation of insulin glargine and Lantus in terms of change of HbA1c from baseline to endpoint (scheduled at month 6 [week 26]) in japanese patients with type 1 diabetes mellitus

Secondary Objectives:

To compare a new formulation of insulin glargine and Lantus in terms of change in fasting plasma glucose (FPG), preinjection plasma glucose, 8-point self-measured plasma glucose (SMPG) profile.

To compare a new formulation of insulin glargine and Lantus in terms of occurrence of hypoglycemia

Read the detailed description

The duration of study will consist of:

  • Up to 2-week screening period;
  • 6-month open-label comparative efficacy and safety treatment period;
  • 6-month open-label comparative safety extension period;
  • 4-week post-treatment safety follow-up period
03

Conditions studied

  • Type 1 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with type 1 diabetes mellitus

Exclusion criteria

Exclusion criteria:

  • Age \< 18 years at screening visit;
  • \< 7.0 % or > 10.0 % (national glycohemoglobin standardization program [NGSP] value) at screening visit;
  • Patients less than 1 year before screening visit on any basal plus mealtime insulin;
  • Patients not on stable insulin dose (±20% total basal insulin dose) in the last 30 days prior to screening visit;
  • Patients using pre-mix insulins, human regular insulin as mealtime insulin and/or any glucose-lowering drugs other than basal insulin and mealtime rapid-insulin analogue in the last 3 months before screening visit;
  • Use of an insulin pump in the last 6 months before screening visit and/or plan to switch to insulin pump in next 12 months;
  • Severe hypoglycemia resulting in coma/seizures, and/or hospitalization for diabetic ketoacidosis in the last 6 months before screening visit;
  • Unstable proliferative diabetic retinopathy or any other rapidly progressive diabetic retinopathy or macular edema likely to require treatment (eq, laser, surgical treatment or injectable drugs) during the study period.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
243 participants (actual)

Study arms

  • Experimental
    New formulation of insulin glargine

    once daily in the evening on-top of mealtime insulin

    Drug: Insulin glargine new formulation (HOE901)

  • Active comparator
    Lantus (insulin glargine)

    once daily in the evening on-top of mealtime insulin

    Drug: Insulin glargine (HOE901) (Lantus)

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline in HbA1c

    Time frame: baseline, 6 months

Secondary outcomes

  1. Percentage of HbA1c responders (HbA1c < 7%; < 6.5%)

    Time frame: up to 6 months

  2. Change from baseline in FPG

    Time frame: baseline, 6 months

  3. Change from baseline in pre-basal insulin injection SMPG

    Time frame: baseline, 6 months

  4. Change from baseline in 8-point SMPG profiles

    Time frame: baseline, 6 months

  5. Change from baseline in 24-hour mean plasma glucose of SMPG profiles (mean of 8-point values)

    Time frame: baseline, 6 months

  6. Change from baseline in variability of plasma glucose profile

    Time frame: baseline, 6 months

  7. Change from baseline in daily basal insulin dose

    Time frame: baseline, 6 months

  8. Number of Patients with various types of Hypoglycemia Events

    Time frame: up to 6 months

07

Study locations

22 sites
  • Investigational Site Number 392119
    Amagasaki-Shi, Japan
  • Investigational Site Number 392106
    Chuo-Ku, Japan
  • Investigational Site Number 392107
    Chuo-Ku, Japan
  • Investigational Site Number 392110
    Ebina-Shi, Japan
  • Investigational Site Number 392115
    Higashiosaka-Shi, Japan
  • Investigational Site Number 392117
    Izumisano-Shi, Japan
  • Investigational Site Number 392109
    Kamakura-Shi, Japan
  • Investigational Site Number 392101
    Koriyama-Shi, Japan
  • Investigational Site Number 392121
    Kurashiki-Shi, Japan
  • Investigational Site Number 392112
    Nagoya-Shi, Japan
  • Investigational Site Number 392120
    Nishinomiya-Shi, Japan
  • Investigational Site Number 392113
    Osaka-Shi, Japan
  • Investigational Site Number 392116
    Osaka-Shi, Japan
  • Investigational Site Number 392118
    Osaka-Shi, Japan
  • Investigational Site Number 392104
    Shinjuku-Ku, Japan
  • Investigational Site Number 392105
    Shinjuku-Ku, Japan
  • Investigational Site Number 392111
    Shizuoka-Shi, Japan
  • Investigational Site Number 392114
    Takatsuki-Shi, Japan
  • Investigational Site Number 392122
    Tokushima-Shi, Japan
  • Investigational Site Number 392103
    Tomioka-Shi, Japan
  • Investigational Site Number 392102
    Ushiku-Shi, Japan
  • Investigational Site Number 392108
    Yokohama-Shi, Japan
08

References and documents

Publications

  • Matsuhisa M, Koyama M, Cheng X, Takahashi Y, Riddle MC, Bolli GB, Hirose T; EDITION JP 1 study group. New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1). Diabetes Obes Metab. 2016 Apr;18(4):375-83. doi: 10.1111/dom.12619. Epub 2016 Feb 1. PubMed 26662964 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2012, a primary completion of Oct 2013 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2012
First posted
Sep 21, 2012
Start
Sep 2012
Primary completionActual
Oct 2013
CompletionActual
Apr 2014
Last update
Jun 9, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01689129
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Sep 21, 2012
Start date
Sep 2012
Primary completion
Oct 2013
Completion
Apr 2014
Last update
Jun 9, 2014

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin Glargine

Start the discussion